Table of Contents
EAST WINDSOR, N.J. – Aurobindo Pharma has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application deferasirox tablets, 90mg, 180mg, and 360mg. Aurobindo Pharma’s deferasirox tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Jadenu Tablets manufactured by Novartis Pharmaceuticals Corp..
Deferasirox tablets are indicated for the treatment of chronic iron overload due to blood transfusions (transfusional iron overload). They are also indicated for the treatment of chronic iron overload in non-transfusion-dependent thalassemia syndromes.
Deferasirox tablets has an estimated market size of US $46.6 million for the twelve months ending July 2023, as per IQVIA.
